The neurology of cerebral arteriovenous malformations

• Published in: Revue neurologique 2006-12, Vol.162 (12), p.1189-1203
• Main Author: Stapf, C
• Format: Article
• Language: fre
• Subjects: Cerebral Angiography; Embolization, Therapeutic; Humans; Incidence; Intracranial Arteriovenous Malformations - classification; Intracranial Arteriovenous Malformations - epidemiology; Intracranial Arteriovenous Malformations - physiopathology; Intracranial Arteriovenous Malformations - therapy; Morbidity; Neurologic Examination
• ISSN: 0035-3787
• DOI: 10.1016/S0035-3787(06)75133-5

Brain arteriovenous malformations (AVMs) constitute a neurovascular disorder that comes to clinical attention mainly in young adults in their mid thirties. Associated symptoms often require neurological treatment for symptomatic seizures (focal or generalized), headaches (episodic or chronic), progressive neurological deficits, or spontaneous AVM rupture leading to intracerebral, intraventricular, and/or subarachnoid hemorrhage. Little data exist in the medical literature regarding the natural history risk of the disease and no controlled studies are available on the risk of invasive AVM treatment (endovascular, neurosurgery, radiotherapy). This review focuses on all aspects of neurological brain AVM management and discusses possible predictors of the natural history risk as well as the benefit and risk of invasive treatment. AVM patient management is ideally based on a trans-disciplinary approach via a neurovascular team of neurologists, neuroradiologists, neurosurgeons, and radiotherapists. A newly diagnosed AVM does not necessarily represent an a priori indication for interventional treatment. The decision in favor or against therapy mainly depends on clinical criteria (ruptured versus unruptured AVM, neurological exam, patient age and co-morbidity, etc.) and the angioarchitecture of the malformation. The ARUBA study is going to be the first randomized clinical trial comparing the risk of invasive treatment versus non-invasive management.